NECTIN4 (Nectin Cell Adhesion Molecule 4)

[18F]FDG remains the reference PET agent in BC; however, novel agents show encouraging results for improving staging and therapy monitoring. Broader clinical implementation requires multicentric validation and standardized imaging protocols.

Furthermore, analysis of lymph node and distant (liver and peritoneal) metastases revealed significantly higher c-MET and NECTIN4 expression in the metastatic setting. In conclusion, TROP-2 is highly expressed in most PDACs, independent of clinicopathological and genomic parameters, and inversely correlating with PD-L1, making TROP-2 an ideal ADC target.

Analysis of 136 interventional trials reveals a rapidly expanding field dominated by antibody-drug conjugates, particularly in urothelial carcinoma, with significant activity in combination regimens and diverse therapeutic modalities under exploration. These findings emphasize the substantial translational potential of Nectin-4 and highlight key trends shaping its future clinical development.

GTN exhibits frequent expression of several established ADC targets, particularly Nectin4 and FOLR1. These findings provide a molecular rationale for biomarker-driven investigation of ADC-based therapeutic strategies in refractory or recurrent GTN.

The Food and Drug Administration (FDA)-approved Nectin-4-targeted drug, enfortumab vedotin, has demonstrated substantial efficacy in the treatment of UC...In treatment experiments, covalent 177Lu-FZ-NRs strongly inhibited tumor growth without obvious toxicity. In summary, our novel Nectin-4-targeted covalent bicyclic peptide radioligands provide new molecular imaging tools for the non-invasive assessment of Nectin-4 and establish a foundation for UC-targeted radiotherapy.

The broader-than-expected mutational landscape, including recurrent TP53 mutations, alterations in MAPK and PI3K pathways, and notable MYC amplification, further refines current understanding of TAS biology. These findings offer a basis for the development of prospective therapeutic strategies in this rare and aggressive malignancy.

This review summarizes the current role of PET imaging for bladder cancer care, highlighting the strengths and limitations of FDG, and explores future directions, including emerging non-FDG tracers that target alternative aspects of tumor biology, such as specific receptors, fibroblast activation or Nectin-4 expression, which may improve lesion detectability and better characterize disease leading to more precise treatments. In parallel, we discuss key technological advances, including PET/MRI, integration of quantitative PET with radiomics, and artificial intelligence-driven analysis, all of which hold promises for enhancing diagnostic accuracy, refining risk stratification, and supporting personalized clinical decision-making in bladder cancer management.

P3, N=462, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting

We found that tumor samples from patients with cancer of the urinary tract that had spread to the brain had higher expression of a gene called NECTIN4 (67%). Our findings suggest that treatments targeting NECTIN4, such as a drug called enfortumab vedotin with or without pembrolizumab, might benefit patients with brain metastases, especially if their tumors have high NECTIN4 levels.

Using plasma alone, APEX enables classification of prognostically relevant basal and classical pancreatic cancer subtypes and identifies plasma-inferred NECTIN4 expression as a biomarker of response to enfortumab vedotin in metastatic bladder cancer. Together, these findings establish APEX as a biopsy-free approach for profiling tumor transcriptional states and extend liquid biopsy beyond genomic alterations to clinically relevant gene expression programs.

This review focuses on future progress in TNBC therapy that relies on integrating precision antigen targeting, immune cell engineering, and advanced delivery technologies. Together, mRNA-based immunotherapies hold immense promise to overcome current therapeutic barriers and pave the way for more effective, personalized treatment strategies in TNBC.

Treatment with enfortumab vedotin (EV) plus pembrolizumab achieved a complete response after 3 cycles, and remission was maintained with continued therapy. This case suggests that EV plus pembrolizumab may be effective for UC-NE and highlights the importance of evaluating nectin-4 and the tumor immune microenvironment when considering treatment strategies for this rare subtype.